News

Arcturus Therapeutics receives Orphan Drug Designation from U.S. FDA for cystic fibrosis treatment

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for Arcturus Therapeutics' product candidate ARCT-032 to treat cystic fibrosis (CF). The FDA’s...

Novo Nordisk invests in expansion of Chartres production facilities

Novo Nordisk is set to invest more than 16 billion Danish kroner (2.1 billion euros) to expand its existing production site in Chartres, France,...

FDA approves first therapy for rare type of non-cancerous tumors

The U.S. Food and Drug Administration has approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is...